Bryan A. Irving
Oncology · 2012
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 28 citations into it
- Immunology — 25 citations into it
Whom Bryan A. Irving trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Bryan A. Irving overall
Papers from Bryan A. Irving's perspective
Ordered by how strongly the researchers Bryan A. Irving trusts endorse each paper. Same corpus, a different order for every researcher.
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
- The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
- Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. (Immunity)
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (Science Translational Medicine)
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
- Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (Proceedings of the National Academy of Sciences of the United States of America)